DONATE TODAY
May 29, 2019

Rebound of medication abortion in Texas following updated mifepristone label

In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label.
Share
Facebook
LinkedIn
X

Rebound of medication abortion in Texas following updated mifepristone label

https://doi.org/10.1016/j.contraception.2019.01.001

Details
Date
May 29, 2019
Category
Abortion Care
Journal
The journal Contraception
Authors
Sarah E. Baum, Kari White, Kristine Hopkins, Joseph E. Potter, Daniel Grossman
key findings
Citation
Related Publications

Timeline of Family Planning and Abortion Legislation in Texas: 2011 – 2024 

Abortion Care, Research Briefs, Systems of Care, Texas

The Risks of Excluding Qualified Family Planning Providers From Medicaid

Contraception, Journal Articles, Policy Analysis, Providers

Time Pressures and Sociocultural Constraints Affecting Access to Early Abortion Care Under Texas’ “6-Week” Ban

Abortion Care, Contraception, Journal Articles, Providers, Systems of Care

How State Antiabortion Lawsuits and Increased Surveillance Empower Domestic Abusers

Abortion Care, Providers, Research Briefs, Systems of Care

Contact Us

  • 737-381-1260
  • info@resoundrh.org

Advancing equitable reproductive health through rigorous research.

© 2024 Resound Research for Reproductive Health is fiscally sponsored by The Tides Center

PRIVACY POLICY
TERMS OF USE